The strong active-manager buying cluster suggests a shared thesis around CATX's radiopharmaceutical pipeline, but the near-complete exits by Citadel and Walleye create a mixed signal. Monitor upcoming Q4 2024 13F filings to see if the buying persisted or reversed.
Executive Summary
A significant institutional cluster formed in CATX during Q3 2024, with 8 buyers accumulating $13.3M in net new positions (total holdings $20.2M) while 3 sellers reduced holdings by $10.5M. The buying is dominated by active asset managers including Adage Capital Partners ($6.2M add) and multiple doublings by Schwab, AllianceBernstein, and Victory Capital, suggesting a shared bullish thesis on Perspective Therapeutics' radiopharmaceutical pipeline.
Key Financial Metrics
Institutional Positions
Net institutional flow: $2.8M
▲ Buyers (8)
| Institution | Action | Change | Position Value | Value Δ |
|---|---|---|---|---|
| Adage Capital Partners Gp | ADD | +96.5% | $10.0M | $6.2M |
| Schwab | DOUBLED | +221.7% | $5.8M | $4.4M |
| Victory Capital Management | DOUBLED | +328.7% | $674.0K | $556.0K |
| Rhumbline Advisers | ADD | +43.9% | $1.2M | $584.0K |
| Alliancebernstein | DOUBLED | +104.3% | $663.0K | $421.0K |
▼ Sellers (3)
| Institution | Action | Change | Prev Value | Value Δ |
|---|---|---|---|---|
| Citadel | NEAR_EXIT | -97.9% | $5.7M | -$5.6M |
| Walleye Capital | NEAR_EXIT | -96.5% | $5.1M | -$4.9M |
| Strs Ohio | TRIM | -39.1% | $87.0K | -$16.0K |
Key Facts
- 8 institutional buyers accumulated $13.3M in net new CATX positions during Q3 2024
- Adage Capital Partners added $6.2M, the largest single buy, increasing its position by 96.5%
- Schwab doubled its stake (+221.7%), now holding $5.8M
- Victory Capital Management tripled its position (+328.7%)
- Citadel and Walleye Capital each exited ~97% of their positions, selling a combined $10.4M
- Active asset managers dominate the buying side (7 of 8 buyers), not passive rebalancing
Financial Impact
8 institutional buyers added $13.3M in net new CATX positions while 3 sellers reduced holdings by $10.5M, for a net institutional inflow of approximately $2.8M
Risk Factors
- 13F data is 45+ days stale; positions may have been unwound since quarter-end
- Large sellers (Citadel, Walleye) may have material non-public information or a bearish thesis
- Pre-revenue biotech with binary pipeline risk — institutional buying does not guarantee clinical success
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 institutional 13F filing from SEC EDGAR.
| Document | Accession Number |
|---|---|
| INST-CLUSTER Data (Synthetic) | inst-cluster-CATX-2024-Q3 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 3d ago | 8-K | $2.28 | awaiting T+20 | — | — |
Oct 8, 2026 18d ago | 8-K | $2.71 | awaiting T+20 | — | — |
Oct 2, 2026 24d ago | Press Release | $2.76 | awaiting T+20 | — | — |
Sep 14, 2026 6w ago | 8-K | $2.92 $2.52 | ▼ −13.70% | ▼ −15.96% | — |
Sep 11, 2026 6w ago | Press Release | $2.81 $2.66 | ▼ −5.34% | ▼ −7.21% | — |
Sep 8, 2026 6w ago | Insider Cluster | $2.99 $2.46 | ▼ −17.73% | ▼ −19.67% | — |
Sep 4, 2026 7w ago | Insider Cluster | $3.12 $2.36 | ▼ −24.36% | ▼ −26.07% | — |
Sep 4, 2026 7w ago | Insider Cluster | $3.12 $2.36 | ▼ −24.36% | ▼ −26.07% | — |
Aug 10, 2026 10w ago | 8-K | $3.18 $2.99 | ▼ −5.97% | ▼ −4.92% | — |
Jul 17, 2026 14w ago | Press Release | $2.99 $3.20 | ▲ +7.02% | ▲ +2.58% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers